What is Medtronic's revenue?

Medtronic (MDT) generated $36.4B in revenue over the trailing twelve months, up 8.4% year over year.

Is Medtronic profitable?

Medtronic reported $4.8B in net income over the trailing twelve months, a 13.2% net margin.

What are Medtronic's profit margins?

Gross margin is 65.0% and operating margin is 17.8%, with a 13.2% net margin.

What is Medtronic's earnings per share?

Medtronic's diluted EPS over the trailing twelve months is $3.74.

Where does Medtronic's income statement data come from?

Every line is extracted from Medtronic's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Medtronic MDT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q4 '26	Q3 '26	Q2 '26	Q1 '26	Q4 '25
Net interest income	——	$85M-4.5%	$89M-25.8%	$120M—	——
Total revenue	$9.81B+8.8%	$9.02B+0.6%	$8.96B+4.5%	$8.58B-3.9%	$8.93B+7.7%
Total cost of revenue	$3.4B+4.2%	$3.26B+6.5%	$3.06B+2.0%	$3B-4.6%	$3.15B+13.2%
Gross profit	$6.41B+11.3%	$5.76B-2.4%	$5.9B+5.8%	$5.58B-3.5%	$5.78B+4.8%
Gross margin	65.4%+1.5pp	63.8%-2.0pp	65.8%+0.8pp	65%+0.3pp	64.7%-1.7pp
Research and development	$671M-7.1%	$722M-4.2%	$754M+3.9%	$726M+6.1%	$684M+1.3%
Selling, general and administrative	$3.06B+3.4%	$2.96B-0.3%	$2.97B+5.7%	$2.81B+3.2%	$2.72B+0.1%
Depreciation and amortization	$716M-4.4%	$749M+0.5%	$745M-0.4%	$748M-11.0%	$840M+22.8%
Provision for credit losses	——	$36M-5.3%	$38M+35.7%	$28M—	——
Restructuring charges	——	$172M+1,223%	$13M-80.6%	$67M—	——
Goodwill impairment	——	$0—	$0—	$0—	——
Impairment charges	——	$0—	$0—	$0—	——
Other operating expenses	-$260M-643%	-$35M-59.1%	-$22M+68.6%	-$70M—	——
Operating income	$1.87B+27.9%	$1.46B-13.2%	$1.69B+16.7%	$1.45B+0.6%	$1.44B-12.8%
Operating margin	19.1%+2.9pp	16.2%-2.6pp	18.8%+2.0pp	16.8%+0.8pp	16.1%-3.8pp
Interest expense	$176M-2.8%	$181M0.0%	$181M+2.8%	$176M+1.1%	$174M-2.8%
Other income (expense), net	$137M+13.2%	$121M+31.5%	$92M+179%	$33M—	$0-100%
Income before income taxes	$1.83B+30.6%	$1.4B-12.1%	$1.6B+22.7%	$1.3B+3.3%	$1.26B-18.1%
Income tax expense	$575M+126%	$254M+18.1%	$215M-15.7%	$255M+28.1%	$199M-16.0%
Net income	$1.24B+8.8%	$1.14B-16.8%	$1.37B+32.1%	$1.04B-1.5%	$1.06B-18.4%
Net margin	12.7%0.0pp	12.7%-2.7pp	15.3%+3.2pp	12.1%+0.3pp	11.8%-3.8pp
Net income attributable to noncontrolling interests	——	$6M-14.3%	$7M0.0%	$7M—	——
Diluted earnings per share	$0.97+9.0%	$0.89-16.8%	$1.07+32.1%	$0.81-1.2%	$0.82-18.8%
Basic earnings per share	$0.98+10.1%	$0.89-16.8%	$1.07+32.1%	$0.81-2.4%	$0.83-17.8%
Weighted-average shares, diluted	1.3B-0.1%	1.3B+0.1%	1.3B+0.1%	1.3B-0.2%	1.3B+0.3%
Weighted-average shares, basic	1.3B-0.1%	1.3B0.0%	1.3B0.0%	1.3B-0.3%	1.3B+0.2%
Litigation provision	$28.25M0.0%	$28.25M0.0%	$28.25M0.0%	$28.25M-64.4%	$79.25M0.0%
Share-based compensation expense related to employee stock plans	——	$95M-47.8%	$182M+112%	$86M—	——
Pre-tax stock-based compensation cost	——	$95M-47.8%	$182M+112%	$86M—	——
Share-Based Payment Arrangement, Expense, after Tax	——	$77M-49.7%	$153M+115%	$71M—	——
Amortization of capitalized software and acquired intangible assets	$408M-7.5%	$441M-4.8%	$463M+0.9%	$459M-18.6%	$564M+35.6%
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions	——	$0—	$0-100%	$90M—	——
Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months	——	-$7M—	——	-$154M—	——
Dividends declared (in dollars per share)	——	$0.710.0%	$0.710.0%	$0.71—	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	$1.09B-36.1%	$1.7B+137%	$720M—	——
Less: comprehensive income attributable to noncontrolling interest	——	$7M+133%	$3M-62.5%	$8M—	——
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	——	$1.1B-35.8%	$1.71B+134%	$729M—	——
Deferred and other income taxes	——	——	——	$167M+171%	-$235M-70.3%
Depreciation	——	$308M+9.2%	$282M-2.4%	$289M—	——
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	——	$42M+5.0%	$40M-11.1%	$45M—	——
Dividends, Common Stock, Cash	——	$911M+0.1%	$910M0.0%	$910M—	——
Effective tax rates	——	$0.18+34.1%	$0.14-31.1%	$0.2—	——
Share-Based Payment Arrangement, Expense, Tax Benefit	——	$18M-37.9%	$29M+93.3%	$15M—	——
Interest income	——	$17M—	——	——	——
Gross gains	——	$13M—	——	——	——
Equity Method Investment, Realized Loss	——	$22M—	——	——	——
Additions	——	$0-100%	$7M—	——	——
Equity Securities, FV-NI, Settlements	——	$7M—	——	——	——
Foreign Currency Translation and Other Adjustments	——	$82M—	——	$269M—	——
Goodwill impairment losses	——	$0—	$0—	$0—	——
Gross interest expense increase (decrease)	——	——	——	——	——
Income Taxes Paid, Net	$344M+68.6%	$204M-79.4%	$992M+147%	$402M+32.2%	$304M+68.9%
Accounts payable and other current liabilities	$123M-82.5%	$703M+486%	-$182M+69.6%	-$598M-263%	$366M-33.5%
Increase (Decrease) in Inventories	——	$131M-56.2%	$299M-19.8%	$373M—	——
Increase (Decrease) in Other Operating Assets and Liabilities, Net	——	——	$727M+56.7%	$464M—	——
Interest Income (Expense), Operating	——	$85M-4.5%	$89M-25.8%	$120M—	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$201M+548%	$31M-93.3%	$461M+469%	$81M-58.5%	$195M+261%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$888M+57.5%	-$2.09B-428%	-$395M+71.4%	-$1.38B-2.8%	-$1.34B+23.4%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$917M-12.4%	-$816M-69.3%	-$482M+33.0%	-$719M-46.7%	-$490M+41.9%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$2.57B-6.2%	$2.74B+197%	$925M-15.0%	$1.09B-57.0%	$2.53B-1.7%
Net Income Loss Attributable To Noncontrolling Interest	——	$6M-14.3%	$7M0.0%	$7M—	——
Noncontrolling Interest, Decrease from Deconsolidation	——	——	$39M—	——	——
Number of reportable segments	——	——	——	$4—	——
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	——	$110M+143%	-$257M-174%	$349M—	——
Unrealized gains (losses) on hedge instruments	——	-$7M-104%	$167M+230%	-$128M—	——
Other comprehensive income (loss)	——	-$54M-117%	$325M+202%	-$318M—	——
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	——	-$2M+33.3%	-$3M-200%	-$1M—	——
Net investment hedges	——	-$147M-141%	$357M+164%	-$559M—	——
Net unrealized gains (losses) on securities still held	——	-$12M-122%	$55M+189%	$19M—	——
Other Noncash Income (Expense)	-$34M+69.9%	-$113M-1,313%	-$8M+95.0%	-$159M+46.3%	-$296M-164%
Other income, net (Note 6)	$137M+13.2%	$121M+31.5%	$92M+179%	$33M—	$0-100%
Other income, net	-$260M-643%	-$35M-59.1%	-$22M+68.6%	-$70M—	——
Payment for (Proceeds from) Other Investing Activity	——	$24M+117%	-$139M-211%	$125M-9.4%	$138M+23.2%
Payments for Repurchase of Common Stock	$435M+314%	$105M-71.8%	$372M+202%	$123M-55.1%	$274M+51.4%
Payments of Ordinary Dividends, Common Stock	$908M-0.3%	$911M+0.1%	$910M0.0%	$910M+1.4%	$897M0.0%
Payments to Acquire Businesses, Net of Cash Acquired	$406M—	——	——	——	——
Payments to Acquire Investments	$2.15B-9.2%	$2.37B+12.9%	$2.1B0.0%	$2.1B-1.5%	$2.13B+2.8%
Payments to Acquire Property, Plant, and Equipment	$488M+9.9%	$444M-5.1%	$468M-7.1%	$504M+9.8%	$459M-3.6%
Debt issued (Note 13)	——	——	$1.75B—	$0—	——
Proceeds from issuance of shares	——	$164M+2.5%	$160M+68.4%	$95M-12.0%	$108M-35.7%
Financing — other	——	——	——	$70M+125%	-$280M-275%
Short-term borrowings/(repayments) less than 90 days — net	——	——	$753M+16.0%	$649M—	——
Proceeds from disposition of marketable securities and other investments	$2.12B+4.9%	$2.02B+3.9%	$1.95B-3.1%	$2.01B-10.3%	$2.24B+16.8%
Sale of investments	——	$2B+5.3%	$1.9B-5.0%	$2B—	——
Sales of and distributions from equity method investments	——	$21M—	——	——	——
Net additions (releases) charged to costs and expenses	$34M-5.6%	$36M-5.3%	$38M+35.7%	$28M+3.7%	$27M-47.1%
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	——	-$15M-275%	-$4M-122%	$18M—	——
Repayments of Long-Term Debt	——	——	$1.77B+52.2%	$1.16B—	$0—
Research and development expense	$671M-7.1%	$722M-4.2%	$754M+3.9%	$726M+6.1%	$684M+1.3%
Restructuring charges, net	$118M+53.2%	$77M+670%	$10M-77.8%	$45M-69.4%	$147M+242%
Revenue From Contract With Customer Excluding Assessed Tax	$9.81B+8.8%	$9.02B+0.6%	$8.96B+4.5%	$8.58B-3.9%	$8.93B+7.7%
Stock-based compensation	$95M+1.1%	$94M-48.4%	$182M+112%	$86M-3.4%	$89M-9.2%
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	——	$146M+55.3%	$94M+1.1%	$93M—	——
Value of shares repurchased	——	$85M-72.5%	$309M+158%	$120M—	——
EBITDA	$2.59B+17.0%	$2.21B-9.0%	$2.43B+10.9%	$2.19B-3.6%	$2.28B-2.3%
EBITDA margin	26.4%+1.9pp	24.5%-2.6pp	27.1%+1.6pp	25.6%+0.1pp	25.5%-2.6pp
EBIT	$1.87B+27.9%	$1.46B-13.2%	$1.69B+16.7%	$1.45B+0.6%	$1.44B-12.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Medtronic.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medtronic's revenue?: Medtronic (MDT) generated $36.4B in revenue over the trailing twelve months, up 8.4% year over year.
Is Medtronic profitable?: Medtronic reported $4.8B in net income over the trailing twelve months, a 13.2% net margin.
What are Medtronic's profit margins?: Gross margin is 65.0% and operating margin is 17.8%, with a 13.2% net margin.
What is Medtronic's earnings per share?: Medtronic's diluted EPS over the trailing twelve months is $3.74.
Where does Medtronic's income statement data come from?: Every line is extracted from Medtronic's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.